Introduction {#s001}
============

R[at podoplanin]{.smallcaps} (rPDPN) is a recognized lymphatic endothelial cell marker and is expressed on the podocytes of kidney and type I lung alveolar cells.^([@B1])^ rPDPN is a type I transmembrane sialoglycoprotein and induces platelet aggregation via the C-type lectin-like receptor-2 (CLEC-2) of platelets.^([@B5])^ It comprises four platelet aggregation-stimulating (PLAG) domains: PLAG1--3, present in the N-terminus,^([@B1])^ and PLAG4, in the center of the rPDPN protein.^([@B8])^

PMab-2 monoclonal antibody (mAb) was previously produced against PLAG domain of rPDPN^([@B9])^; therefore, PMab-2 could neutralize interactions between rPDPN and CLEC-2.^([@B5])^ PMab-2 is applicable in Western blot, flow cytometry, and immunohistochemical analyses.

In this study, we determined the binding epitope of PMab-2 to rPDPN using flow cytometry and enzyme-linked immunosorbent assay (ELISA).

Materials and Methods {#s002}
=====================

Cell line {#s003}
---------

Chinese hamster ovary (CHO)-K1 was purchased from the American Type Culture Collection (ATCC, Manassas, VA). CHO/rPDPN was produced in our previous study.^([@B9])^ The rPDPN mutation plasmids were transfected into CHO-K1 cells using Lipofectamine LTX (Thermo Fisher Scientific, Inc., Waltham, MA). CHO/rPDPN and transiently transfected cells were cultured in RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto, Japan), supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific, Inc.), 100 U/mL of penicillin, 100 μg/mL of streptomycin, and 25 μg/mL of amphotericin B (Nacalai Tesque, Inc.) at 37°C in a humidified atmosphere of 5% carbon dioxide and 95% air.

Production of rPDPN point mutants {#s004}
---------------------------------

The complementary DNA of rPDPN was subcloned into a pcDNA3 vector (Thermo Fisher Scientific, Inc.). Substitutions of amino acids to alanine in rPDPN sequence were performed by the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA).

Flow cytometry {#s005}
--------------

Cells were harvested after brief exposure to 0.25% trypsin/1 mM ethylenediaminetetraacetic acid (Nacalai Tesque, Inc.). After washing with 0.1% bovine serum albumin in phosphate-buffered saline (PBS), the cells were treated with PMab-2 for 30 minutes at 4°C, followed by treatment with Alexa Fluor 488-conjugated anti-mouse IgG (1:1000; Cell Signaling Technology, Inc., Danvers, MA). Fluorescence data were acquired using the Cell Analyzer EC800 (Sony Corp., Tokyo, Japan).

Enzyme-linked immunosorbent assay {#s006}
---------------------------------

Synthesized rPDPN peptides using PEPscreen (Sigma-Aldrich Corp., St. Louis, MO) were immobilized on Nunc MaxiSorp 96-well immunoplates (Thermo Fisher Scientific, Inc.) at 10 μg/mL for 30 minutes at 37°C. After blocking with Superblock T20 (PBS) blocking buffer (Thermo Fisher Scientific, Inc.), the plates were incubated with purified PMab-2 (10 μg/mL), followed by a 1:2000 dilution of peroxidase-conjugated anti-mouse IgG (Agilent Technologies, Inc.). The enzymatic reaction was conducted using 1-Step Ultra TMB-ELISA (Thermo Fisher Scientific, Inc.). Optical density was measured at 655 nm using an iMark Microplate Reader (Bio-Rad Laboratories, Inc., Berkeley, CA). These reactions were performed at 37°C with a total sample volume of 50--100 μL.

Immunohistochemical analyses {#s007}
----------------------------

Histological sections (4 μm thick) of rat tissues were directly autoclaved in citrate buffer (pH 6.0; Nichirei Biosciences, Inc., Tokyo, Japan) for 20 minutes. After blocking with Superblock T20 (PBS) blocking buffer, sections were incubated with PMab-2 (1 μg/mL) or PMab-2 (1 μg/mL) plus peptides (5 μg/mL) for 1 hour at room temperature, treated using an EnVision+ Kit (Agilent Technologies, Inc.) for 30 minutes. Color was developed using 3,3-diaminobenzidine tetrahydrochloride (Agilent Technologies, Inc.) for 2 minutes and counterstained with hematoxylin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan).

Results and Discussion {#s008}
======================

We previously developed a mouse anti-rPDPN mAb, PMab-2, by immunizing the PLAG domain of rPDPN.^([@B9])^ In this study, we produced point mutants of rPDPN using recombinant proteins and synthesized peptides and investigated the epitope of PMab-2 critical for rPDPN detection.

We produced a series of point mutants of rPDPN using a QuikChange Lightning Site-Directed Mutagenesis Kit because PMab-2 was produced by immunizing mice with amino acids 38--51 of rPDPN. Using flow cytometry, we found that PMab-2 recognized G38A, D39A, D40A, M41A, V42A N43A, P44A, G45A, D48A, R49A, I50A, and E51A ([Fig. 1](#f1){ref-type="fig"}). However, it did not recognize L46A and E47A, thus indicating that Leu46 and Glu47 of rPDPN are crucial for PMab-2 detection.

![Epitope mapping of PMab-2 using point mutants of rPDPN. Point mutants of rPDPN were analyzed using flow cytometry. Point mutants were expressed on CHO-K1 cells and were then incubated with PMab-2 (2 μg/mL) or buffer control for 30 minutes at 4°C, followed by treatment with corresponding secondary antibodies.](fig-1){#f1}

Next, we synthesized a series of peptides: point mutants of 38--51 amino acids of rPDPN ([Table 1](#T1){ref-type="table"}). Using ELISA, we found that PMab-2 detected G38A, D39A, D40A, M41A, V42A N43A, P44A, G45A, D48A, R49A, I50A, and E51A; in contrast, it did not recognize L46A and E47A, thus confirming the result obtained via flow cytometry.

###### 

[Determination of PMab-2 Epitope by Enzyme-Linked Immunosorbent Assay]{.smallcaps}

  *Mutation*   *Sequence*       *PMab-2*
  ------------ ---------------- ----------
  G38A         ADDMVNPGLEDRIE   +++
  D39A         GADMVNPGLEDRIE   +++
  D40A         GDAMVNPGLEDRIE   +++
  M41A         GDDAVNPGLEDRIE   +++
  V42A         GDDMANPGLEDRIE   +++
  N43A         GDDMVAPGLEDRIE   \+
  P44A         GDDMVNAGLEDRIE   +++
  G45A         GDDMVNPALEDRIE   \+
  L46A         GDDMVNPGAEDRIE   −
  E47A         GDDMVNPGLADRIE   −
  D48A         GDDMVNPGLEARIE   +++
  R49A         GDDMVNPGLEDAIE   +++
  I50A         GDDMVNPGLEDRAE   +++
  E51A         GDDMVNPGLEDRIA   +++

+++, OD655≧1.0; +, 0.1≦OD655\<0.6; −, OD655\<0.1.

We performed a blocking assay using immunohistochemistry. PMab-2 reacted with type I alveolar cells ([Fig. 2](#f2){ref-type="fig"}), renal podocytes ([Fig. 3](#f3){ref-type="fig"}), and lymphatic endothelial cells of colon ([Fig. 4](#f4){ref-type="fig"}). These reactions were completely or partially neutralized by G38A; in contrast, L46A and E47A did not block the reactions of PMab-2 with rat tissues, thus indicating that L46A and E47A of rPDPN are critical for PMab-2 detection.

![Immunohistochemical analyses using rat lung tissues. Histological sections of lung were directly autoclaved in citrate buffer for 20 minutes. After blocking with blocking buffer, sections were incubated with PMab-2 (1 μg/mL) or PMab-2 (1 μg/mL) plus peptides (5 μg/mL), followed by an EnVision+ Kit. Scale bar = 100 μm. HE, hematoxylin and eosin.](fig-2){#f2}

![Immunohistochemical analyses using rat kidney tissues. Histological sections of kidney were directly autoclaved in citrate buffer for 20 minutes. After blocking with blocking buffer, sections were incubated with PMab-2 (1 μg/mL) or PMab-2 (1 μg/mL) plus peptides (5 μg/mL), followed by an EnVision+ Kit. Scale bar = 100 μm.](fig-3){#f3}

![Immunohistochemical analyses using rat colon tissues. Histological sections of colon were directly autoclaved in citrate buffer for 20 minutes. After blocking with blocking buffer, sections were incubated with PMab-2 (1 μg/mL) or PMab-2 (1 μg/mL) plus peptides (5 μg/mL), followed by an EnVision+ Kit. Scale bar = 100 μm.](fig-4){#f4}

In addition, we performed a blocking assay using flow cytometry and found that PMab-2 reacted with the CHO/rPDPN cell line ([Fig. 5](#f5){ref-type="fig"}). This reaction was completely neutralized by G38A; in contrast, L46A and E47A did not block the reaction of PMab-2 with CHO/rPDPN, which indicated that Leu46 and Glu47 of rPDPN are critical for PMab-2 detection.

![Flow cytometry using PMab-2 and point mutants of rPDPN. PMab-2 (1 μg/mL) or PMab-2 (1 μg/mL) + peptides (G38A, L46A, and E47A; 10 μg/mL) were treated with CHO/rPDPN cells for 30 minutes at 4°C, followed by addition of secondary antibodies.](fig-5){#f5}

Taken together, the critical epitope of PMab-2 comprises Leu46 and Glu47 of rPDPN ([Fig. 6](#f6){ref-type="fig"}). These findings could be applied to the production of more functional anti-rPDPN mAbs.

![Illustration of rPDPN and epitope of PMab-2. rPDPN possesses four PLAG domains. PMab-2 was established by immunizing PLAG2--3 domains. Leu46 and Glu47 are critical amino acids for PMab-2 recognition to rPDPN. PLAG, platelet aggregation stimulating.](fig-6){#f6}
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